|1.||Weller, Michael: 11 articles (11/2014 - 12/2009)|
|2.||Stupp, Roger: 11 articles (09/2014 - 09/2007)|
|3.||Mikkelsen, Tom: 9 articles (10/2015 - 05/2007)|
|4.||Reardon, David A: 7 articles (05/2015 - 08/2008)|
|5.||Picard, Martin: 6 articles (05/2015 - 12/2008)|
|6.||Kurozumi, Kazuhiko: 6 articles (04/2014 - 08/2008)|
|7.||Nabors, L Burt: 5 articles (05/2015 - 05/2007)|
|8.||Hegi, Monika E: 5 articles (05/2015 - 09/2007)|
|9.||Ichikawa, Tomotsugu: 5 articles (04/2014 - 01/2012)|
|10.||Date, Isao: 5 articles (04/2014 - 01/2012)|
|1.||Glioblastoma (Glioblastoma Multiforme)
12/01/2006 - "Cilengitide is highly effective in suppressing blood vessel growth, thereby controlling orthotopic growth of this glioblastoma cell line."
05/01/2015 - "End of the road: confounding results of the CORE trial terminate the arduous journey of cilengitide for glioblastoma."
05/01/2015 - "Two cilengitide regimens in combination with standard treatment for patients with newly diagnosed glioblastoma and unmethylated MGMT gene promoter: results of the open-label, controlled, randomized phase II CORE study."
09/01/2014 - "Cilengitide combined with standard treatment for patients with newly diagnosed glioblastoma with methylated MGMT promoter (CENTRIC EORTC 26071-22072 study): a multicentre, randomised, open-label, phase 3 trial."
03/01/2014 - "Using a standardized approach, we analyzed patterns of progression on MRI in 21 patients enrolled onto a phase 2 trial of cilengitide added to TMZ/RT → TMZ in newly diagnosed glioblastoma. "
01/14/2015 - "Also, this dimer bound 3650-fold stronger and inhibited tumor cell migration and proliferation compared with cilengitide, an integrin-targeting peptidomimetic that performed poorly in recent clinical trials, suggesting promise for further therapeutic development. "
08/01/2002 - "Cilengitide alone did not alter tumor growth when compared with untreated mice, but CMRIT with Cilengitide increased efficacy of treatment, with the cure rate for mice that received 260 mu Ci RIT increasing from 15 to 53% (P = 0.011). "
12/01/2014 - "This study aimed to develop a cilengitide population pharmacokinetic model using nonlinear mixed-effects modeling of 136 adult patients with advanced solid tumors and to scale the pharmacokinetic parameters to the pediatric population. "
08/01/2013 - "MicroSPECT imaging studies demonstrated that uptake of (99m)Tc-NC100692 in the intracranial tumor model was both blocked and displaced by the αvβ3-targeted therapeutic cilengitide. "
06/01/2013 - "Supportive in vitro studies indicate that cilengitide both inhibits tumor cell attachment and increases endothelial permeability. "
08/01/2013 - "Here, we investigated the therapeutic efficacy of RAMBO and cilengitide, an integrin inhibitor, combination therapy for malignant glioma. "
08/01/2013 - "The integrin inhibitor cilengitide enhances the anti-glioma efficacy of vasculostatin-expressing oncolytic virus."
10/01/2013 - "The Children's Oncology Group ACNS0621 study thus evaluated whether cilengitide is active as a single agent in the treatment of children with refractory high-grade glioma (HGG). "
10/01/2013 - "Phase II study of cilengitide in the treatment of refractory or relapsed high-grade gliomas in children: a report from the Children's Oncology Group."
08/01/2013 - "These results indicate that cilengitide enhanced vasculostatin-expressing OV therapy for malignant glioma and provide a rationale for designing future clinical trials combining these two agents."
|4.||Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung)
02/01/2013 - "Randomized phase II study of three doses of the integrin inhibitor cilengitide versus docetaxel as second-line treatment for patients with advanced non-small-cell lung cancer."
03/01/2011 - "In addition, randomized controlled Phase II studies with cilengitide are ongoing for non-small-cell lung cancer and squamous cell carcinoma of the head and neck. "
08/01/2006 - "We conclude that radiation induces expression of alpha v beta 3 integrin in endothelial and non-small-cell lung cancer models, and that integrin antagonist Cilengitide is a radiosensitizer in proportion to the levels of target integrin expression."
08/01/2006 - "Integrin alpha v beta 3 antagonist Cilengitide enhances efficacy of radiotherapy in endothelial cell and non-small-cell lung cancer models."
08/01/2015 - "This multicentre, open-label, randomized, controlled phase II study evaluated cilengitide in combination with cetuximab and platinum-based chemotherapy, compared with cetuximab and chemotherapy alone, as first-line treatment of patients with advanced non-small-cell lung cancer (NSCLC). "
|5.||Melanoma (Melanoma, Malignant)
04/01/2008 - "The results indicated that cilengitide and TMZ exerted synergistic antiproliferative effects against melanoma and endothelial cells in vitro and induced a statistically significant reduction of in vivo melanoma growth with respect to treatment with the methylating agent only. "
08/01/2012 - "We conducted a randomized phase II trial in patients with metastatic melanoma to evaluate the clinical efficacy of cilengitide. "
08/01/2012 - "Cilengitide was well tolerated by patients in both the treatment arms but had minimal clinical efficacy as a single-agent therapy for metastatic melanoma, and the efficacy was not related to baseline αvβ3 expression."
04/01/2008 - "To this end, the influence of cilengitide and TMZ on malignant melanoma growth and endothelial cell proliferation were investigated, using in vitro and in vivo models. "
04/01/2008 - "In conclusion, this study proposes the use of cilengitide in combination with TMZ for the treatment of metastatic melanoma, thereby opening novel perspectives for the use of integrin inhibitors to enhance the efficacy of chemotherapy."
|5.||cyclic arginine-glycine-aspartic acid peptide
|8.||Integrin beta3 (GPIIIa)
|1.||Drug Therapy (Chemotherapy)
|4.||Heterologous Transplantation (Xenotransplantation)